You are here:
Tumor Immunology, T Cell Engineering
- Preclinical cancer models to analyze the efficacy of TCR gene therapies.
- Engineering of T cell specificity - vector design, modification of TCR chains.
- Evaluation of antigens as targets of TCR-modified T cells
Professor Dr. rer. nat. Matthias Leisegang is Junior Professor for Adoptive T Cell Therapy at the Institute of Immunology, Charité - Universitätsmedizin Berlin.